Synvivia applies chemical control over cell behavior
Synvivia applies chemical control over cell behavior. This allows us to optimize biomanufacturing of high-value biopharmaceutical products.
Key people at Synvivia.
Synvivia was founded by Gabriel Lopez (Founder/CEO).
Synvivia was founded by Gabriel Lopez (Founder/CEO).
Key people at Synvivia.
Synvivia is a synthetic biology company that develops genetically encoded protein switches to exert precise chemical control over cell behavior, primarily targeting gene therapy manufacturing and biocontainment applications. Their technology enables turning engineered organisms on or off using small molecules, addressing critical safety and control challenges in synthetic biology. Synvivia serves biotechnology firms and researchers involved in gene therapy and synthetic biology, providing tools to optimize cell function and ensure safe deployment of engineered organisms outside laboratory settings. The company has demonstrated growth momentum through academic validation, industrial partnerships, and backing by prominent investors such as Y Combinator and the National Institutes of Health[1][2][4].
Founded in 2015 by Gabriel Lopez, PhD, a UC Berkeley bioengineering alumnus, Synvivia’s technology originated from Lopez’s doctoral and postdoctoral research focused on protein engineering to control biological functions post-translationally. The foundational technology was co-invented with UC Berkeley Professor John Anderson and developed with support from NSF and DARPA grants. Early traction included participation in Y Combinator’s 2016 cohort and incubation at the QB3-East Bay Innovation Center, helping transition the technology from academic research to commercial application[1][4].
Synvivia rides the growing trend of synthetic biology and gene therapy, where controlling engineered cell behavior is paramount for safety and efficacy. The timing is critical as gene therapies and synthetic organisms move toward broader clinical and commercial use, demanding robust biocontainment and functional control technologies. Market forces such as increased regulatory scrutiny, demand for safer biotech products, and advances in protein engineering favor Synvivia’s approach. By enabling practical control over engineered organisms, Synvivia influences the synthetic biology ecosystem by reducing barriers to adoption and enabling new applications previously limited by safety concerns[1][4].
Looking ahead, Synvivia is poised to expand its impact by scaling its protein switch platform across diverse synthetic biology applications beyond gene therapy manufacturing, potentially including agriculture, industrial biotech, and therapeutics. Trends such as increased investment in cell and gene therapies, regulatory emphasis on biocontainment, and advances in molecular engineering will shape their trajectory. Their influence may evolve from a niche biotech enabler to a foundational technology provider that transforms how engineered organisms are controlled and safely deployed, echoing their founder’s vision of revolutionizing synthetic biology akin to how transistors transformed electronics[4].
